Jazz Pharmaceuticals, Ziihera, zanidatamab-hrii, HER2-positive cancer, gastroesophageal adenocarcinoma, GEA, HERIZON-GEA-01, Phase 3 clinical trial, overall survival, tislelizumab

Dublin, Ireland, and Madrid, Spain, October 23, 2026 Jazz Pharmaceuticals has reported sustained three-year survival outcomes for Ziihera® (zanidatamab-hrii)-based...